Skip to main content
. 2020 Aug 12;111(10):3714–3725. doi: 10.1111/cas.14580

FIGURE 1.

FIGURE 1

Cumulative incidence of MR4.5 over 36 mo relative to the CCI risk score. Cumulative incidence of MR4.5 over 36 mo in the entire cohort (A), the imatinib cohort (B), and the 2GTKI cohort (C). 2GTKI, second‐generation tyrosine kinase inhibitor; CCI, Charlson Comorbidity Index